Inovio Pharmaceuticals (NASDAQ:INO) Releases Earnings Results, Beats Expectations By $0.15 EPS

Inovio Pharmaceuticals (NASDAQ:INO) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.15, FiscalAI reports.

Here are the key takeaways from Inovio Pharmaceuticals’ conference call:

• Positive Sentiment: INO-3107’s FDA review remains on track for the October 30, 2026 PDUFA date; late-cycle review and pre-licensure inspections are complete, with only one reported inspection observation that the company believes it has addressed.
• Positive Sentiment: Inovio is advancing launch preparations for INO-3107, including label negotiations expected to begin in September, medical science liaison activities, and a commercialization agreement with Syneos Health. If approved, the company expects seven years of orphan-drug market exclusivity.
• Negative Sentiment: The FDA has not yet indicated whether INO-3107 qualifies for accelerated approval, and feedback on the confirmatory-trial design remains outstanding. The company continues to characterize approval and launch timing as potential outcomes rather than assured results.
• Negative Sentiment: Inovio ended the quarter with $36.7 million in cash, cash equivalents, and short-term investments, and expects approximately $18 million of operational net cash burn in Q3. July’s $18.3 million equity offering extends funding into late Q1 2027 and through a potential launch, but the company noted that this projection excludes future capital raises.
• Positive Sentiment: Partner ApolloBio reported positive pivotal Phase III results for VGX-3100 in cervical dysplasia, meeting its primary efficacy endpoint and supporting plans for a potential regulatory filing in China. Inovio also reported encouraging preclinical progress for its DPROT platform in hemophilia A and other rare diseases.

Inovio Pharmaceuticals Trading Up 2.0%

Shares of NASDAQ:INO traded up $0.02 during trading on Friday, hitting $0.92. 1,457,986 shares of the stock were exchanged, compared to its average volume of 2,352,324. The company has a market cap of $75.52 million, a PE ratio of -1.01 and a beta of 1.52. The company has a fifty day moving average price of $1.03 and a two-hundred day moving average price of $1.30. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.98.

Wall Street Analysts Forecast Growth

INO has been the topic of several recent research reports. Piper Sandler reaffirmed an “overweight” rating and issued a $4.00 price objective on shares of Inovio Pharmaceuticals in a report on Monday, August 3rd. Wall Street Zen cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, June 21st. HC Wainwright reissued a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Thursday. Jefferies Financial Group upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and lifted their target price for the company from $1.80 to $3.00 in a report on Thursday. Finally, Weiss Ratings upgraded Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $3.17.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of INO. AQR Capital Management LLC acquired a new stake in Inovio Pharmaceuticals during the 1st quarter worth approximately $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Inovio Pharmaceuticals by 39.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 5,894 shares during the last quarter. Qube Research & Technologies Ltd bought a new position in Inovio Pharmaceuticals in the 2nd quarter worth about $234,000. Jane Street Group LLC raised its position in shares of Inovio Pharmaceuticals by 221.2% during the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock worth $81,000 after buying an additional 27,329 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in Inovio Pharmaceuticals by 1,667.1% during the third quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company’s stock worth $153,000 after buying an additional 61,516 shares in the last quarter. 26.79% of the stock is currently owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.